The Advanced Addiction Psychopharmacology Course
We will be coming together virtually in 2021!
The live webinar Q&A session for this virtual course will be held on Saturday, November 6, 2021 and Saturday, November 13, 2021.
Registered for this course?
Who Should Attend?
This course is designed for physicians and other health care professionals who have a foundation in prescribing medication for patients with substance use disorders, including those with co-occurring psychiatric conditions, but would like a deeper understanding of these pharmacotherapies.
This course is designed for learners with a foundational knowledge of addiction psychiatry. Learners who attend this activity will receive a more in-depth educational experience in addiction psychopharmacology.
After participating in this course, learners should be able to:
- Describe how to use methadone, buprenorphine and naltrexone in clinical practice for the treatment of opioid use disorders.
- Describe medication treatments for alcohol use disorders.
- Determine when to use varenicline, bupropion, and nicotine replacement therapy (NRT) for treatment of nicotine use disorders.
- Discuss new evidence for medication treatments for cocaine and methamphetamine use disorder.
- Discuss new evidence for medication treatments for cannabis use disorder.
- Discuss medication approaches for the treatment of sedative-hypnotic use disorder.
- List evidence-based options for anti-depressant and anti-anxiety pharmacotherapy when treating patients with a co-occurring substance use disorder.
- Discuss evidence-based pharmacotherapy for treatment of ADHD with co-occurring substance use disorders.
- Discuss the pharmacotherapy of bipolar disorder in patients with co-occurring substance use disorder.
ADHD Pharmacotherapy with Co-Occurring Substance Use Disorder
Evidence vs. Assumptions
Alcohol Use Disorder Pharmacotherapy
From Detox to Relapse Prevention; Medication Treatments for AUD
Anti-Depressant and Anti-Anxiety Pharmacotherapy with Co-Occurring Substance Use Disorder
Evidence-Based Medication Options
Bipolar Disorder Pharmacotherapy with Co-Occurring Substance Use Disorder
Co-Morbidity is More Common Than Not
Cannabis Use Disorder Pharmacotherapy
Promising Approaches on the Horizon
Nicotine Use Disorder Pharmacotherapy
An Underused Arsenal: Varenicline, Bupropion, and NRT
Opioid Use Disorder Pharmacotherapy
How to use Methadone, Buprenorphine and IM-Naltrexone (MOUD) in Clinical Practice
Sedative-Hypnotic Use Disorder Pharmacotherapy
Inpatient and Outpatient Medication Approaches
Stimulant Use Disorder Pharmacotherapy
Clinical Effects and Treatment Issues
Christina A. Brezing, MD is an Assistant Professor of Psychiatry in the Division on Substance Use Disorders at Columbia University Irving Medical Center and a Research Scientist at New York State Psychiatric Institute where she studies how applications of different technology improves the assessment and treatment of substance use disorders. She is the Principal Investigator of a NIDA-funded grant to study novel pharmacotherapy and applications of technology in the treatment of Cannabis Use Disorder. She was a Columbia Hadar Fellow and has received research support through the Columbia Smither’s Foundation, the Dartmouth Center for Technology and Behavioral Health, and the American Psychiatric Institute for Research and Education. She has served as a co-investigator or study physician on numerous NIDA-funded medication treatment trials for substance use disorders at Columbia’s Substance Treatment and Research Services (STARS) program, and clinically, she treats patients with severe and persistent mental illness and co-occurring substance use disorders. She is the director of the addiction curriculum for the Columbia psychiatry residency and co-director of the curriculum for the Columbia ACGME-T32 Substance Use Disorder Fellowship and the American Academy of Addiction Psychiatry’s Advanced Addiction Psychopharmacology course.
Dr. Brezing attended Duke University for her undergraduate degree in biology with a focus in biochemistry, and completed her medical degree at the University of Florida where she graduated Alpha Omega Alpha and with honors in research. She completed the Howard Hughes Medical Institute-National Institutes of Health (HHMI-NIH) Research Scholars Program studying neuroimaging of impulse control disorders, including pathological gambling, compulsive sexual behavior, and shopping. She completed psychiatry residency at Harvard Medical School-Massachusetts General Hospital and McLean Hospital, where she served as chief resident in addiction, in addition to a National Institute on Drug Abuse (NIDA) funded T32 research fellowship in Addiction Psychiatry at Columbia University and New York State Psychiatric Institute. She is double board certified in adult and addiction psychiatry.
Kevin M. Gray, MD, is Assistant Provost for Research Advancement and a Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina (MUSC). Dr. Gray leads strategic institutional research endeavors and facilitates academic-industry and inter-institutional collaborations. As a child and adolescent psychiatrist and physician-scientist co-leading the MUSC Youth Collaborative, he conducts National Institutes of Health (NIH) supported clinical research, contributing novel advances to treatments for substance use disorders in adolescents and young adults. Dr. Gray serves on the Board of Directors for the American Academy of Addiction Psychiatry, is Associate Editor of the Journal of Child and Adolescent Psychopharmacology, and is Principal Investigator (PI) of the American Academy of Child and Adolescent Psychiatry Physician Scientist Program in Substance Use. In addition to clinical, administrative, and research efforts, Dr. Gray is dedicated to education, providing didactic instruction across training programs and mentoring multiple junior faculty and trainees in clinical research. Dr. Gray’s current research activities include serving as PI/Co-PI of 7 NIH grants, Associate PI of MUSC’s NIH Clinical and Translational Science Award, and Site MPI, Co-Investigator, and Primary Mentor across 8 other NIH grants. Dr. Gray has >100 peer-reviewed publications, 14 published book chapters, and >100 conference presentations
Frances Rudnick Levin, MD is the Kennedy-Leavy Professor of Psychiatry at Columbia University and the Chief of the Division on Substance Use Disorders at NYSPI/Columbia University. For over twenty years, she served as the Director of the Addiction Psychiatry Fellowship Program at New York Presbyterian Hospital for over 20 years and for the past sixteen years, she has been the PI of a T32 NIDA funded Substance Abuse Research Fellowship which has been continuously funded since 1994. Dr. Levin graduated from Cornell University Medical College and completed her psychiatric residency at the New York Hospital-Payne Whitney Clinic. Subsequently, she graduated from a 2-year combined clinical and research fellowship at the University of Maryland and the Addiction Research Center, the intramural branch of the National Institute on Drug Abuse (NIDA). Currently, she serves as the Medical Director of the Providers’ Clinical Support System-Medication Assisted Treatments (PCSS-MAT), a SAMHSA-supported national training and mentoring initiative focused on addressing the opioid use disorder crisis. Also, she is the Medical Director of a SAMHSA-supported State Targeted Response technical assistance grant to states that received funding to address the national opioid epidemic.
Dr. Levin, working with other senior faculty, inaugurated the university-wide Center for Healing of Opioid and Other Substance Use Disorders: Enhancing Intervention Development and Implementation (CHOSEN) in 2020 and serves as one of the senior Directors. Moreover, she is the principal investigator of several federal grants, including a K24 Mid-Career Investigator Award as well as a Co-Investigator on numerous other grants.
Her current research interests include pharmacologic and psychotherapeutic treatment interventions for opioid, cocaine and marijuana use disorders, and treatment approaches for adults with substance use disorders and attention-deficit hyperactivity disorder along with other psychiatric illnesses. Dr. Levin has over two-hundred and sixty articles and book chapters on a wide range of topics including treatments of substance use disorders, assessment and treatment of co-occurring psychiatric illnesses and vulnerabilities associated with substance use disorders. She has served on several advisory panels and ad-hoc federal grant review groups and was as a member of the NIDA – Initial Review Group: Training and Career Development Subcommittee for eight years and served as a member to the NIDA Interventions to Prevent and Treat Addiction (IPTA). She is currently on the Board of Directors for the American Academy of Addiction Psychiatry (AAAP), the College on Drug Dependence (CPDD) and the American Society of ADHD and Related Disorders (APSARD). She is an editorial board member of three journals, past President of the American Academy of Addiction Psychiatry and past Chair of the APA Council on Addiction Psychiatry. She recently co-edited the sixth edition of the APA’s textbook on substance use disorder treatment, a one-stop reference for evidence-based information on neurobiology, assessment, treatment, and research trends in SUDs.
John J. Mariani, MD is an Associate Professor of Clinical Psychiatry at the Columbia University Vagelos College of Physicians and Surgeons and a Research Psychiatrist at the New York State Psychiatric Institute (NYSPI). Dr. Mariani is the Director of the Substance Treatment and Research Service (STARS) in the Division on Substance Use Disorders at the NYSPI/Columbia University Irving Medical Center. Dr. Mariani attended the New York University School of Medicine, completed a psychiatry residency at the Beth Israel Medical Center/Albert Einstein College of Medicine, and an addiction psychiatry clinical and research fellowship at Columbia University Medical Center and the New York State Psychiatric Institute. He serves on the board of the American Academy of Addiction Psychiatry and is the medical advisor to the Major League Baseball Players Association. Dr. Mariani’s research is focused on the development of novel medication treatments for substance use disorders and related co-occurring psychiatric disorders. He has received grant funding from the National Institute on Drug Abuse (NIDA), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), as well as private foundations. Dr. Mariani has over 50 peer-reviewed scientific publications, in addition to a dozen book chapters on the treatment of substance use disorders.
Larissa Mooney, MD is an Associate Professor in the Department of Psychiatry and Biobehavioral Sciences, Director of the Addiction Psychiatry Division, and Director of the UCLA-VA Addiction Psychiatry Fellowship Program at the University of California, Los Angeles (UCLA). Dr. Mooney was the Section Chief for Substance Use Disorders at the Greater Los Angeles VA from 2015-2021. She is the President-Elect of the American Academy of Addiction Psychiatry (AAAP), a Distinguished Fellow of the American Psychiatric Association (APA), and a fellow of the American Society of Addiction Medicine (ASAM). Dr. Mooney has conducted research at UCLA Integrated Substance Abuse Programs (ISAP) on pharmacological and behavioral treatment interventions for addictive disorders. She is one of two Principal Investigators for the Greater Southern California Node of the National Institute on Drug Abuse (NIDA) Clinical Trials Network. She has current NIDA funding to study functional outcomes in cannabis users and treatment interventions for opioid use disorder and stimulant use disorder.
Dr. Nunes is Professor of Psychiatry at Columbia University Medical Center and New York State Psychiatric Institute (NYSPI), Multiple PI of the Greater New York Node of the NIDA Clinical Trials Network (CTN), and Co-Director of the CHOSEN Center at Columbia University. He is a practicing psychiatrist Board Certified in Addiction Psychiatry and Addiction Medicine. He has devoted his career to research on the treatment of opioid, cocaine and other substance use disorders and is nationally and internationally recognized for his work on the evaluation and treatment of co-occurring depression and other psychiatric disorders among patients with substance use disorders and the development of pharmacological and behavioral treatments for substance use disorders, as well as for his work in the CTN testing the effectiveness of behavioral and pharmacological treatments in community-based treatment settings. Dr. Nunes has extensive experience with the design, conduct and analysis of clinical trials of treatments for opioid use disorder, including technology-based interventions and extended-release injections and implants of buprenorphine and naltrexone.
Dr. Rosenthal is Professor and Inaugural Director of Addiction Psychiatry at Renaissance School of Medicine at Stony Brook University. In that role, he oversees the delivery of addiction services for the Stony Brook Health system and is responsible for addiction-related clinical training for medical students, residents and practitioners. Over his career, he has been active in research, education, program development, treatment and public policy related to addiction. Since 2003, he has been the Head of Public Policy at the American Academy of Addiction Psychiatry.
Dr. Rosenthal earned his master’s degree in physiology and pharmacology at Duke University, where he was the recipient of a National Institutes of Health Neurosciences Training Grant Award. He then earned his medical degree at State University of New York Downstate Medical Center and completed his residency in psychiatry at Mount Sinai Hospital, where he served as Chief Resident. After residency, he founded and directed the Addiction Psychiatry program at Beth Israel Medical Center, NY. More recently, he was chair of psychiatry 2001-2014 at the former St. Luke’s Roosevelt Medical Center, NY.
Dr. Rosenthal is a member of numerous professional societies and served as President of both the American Academy of Addiction Psychiatry and the American Association for Technology in Psychiatry. He is a Distinguished Life Fellow of the American Psychiatric Association, and a Distinguished Fellow of the American Academy of Addiction Psychiatry. He has published articles in many professional journals as well as numerous book chapters and books. He is also an Editor of the American Society of Addiction Medicine Principles of Addiction Medicine. In 2008, Dr. Rosenthal was the recipient of the Founders’ Award from the American Academy of Addiction Psychiatry and has been selected for Castle Connolly America’s Top Doctors™ since 2008.
Dr. Sevarino trained in psychiatry in the dual clinical/basic research tract at the Yale University School of Medicine. For six years thereafter, he was PI on NIH grants examining neurobiological mechanisms underlying cocaine dependence, and since then has transitioned to being a clinician-educator who remained active in clinical research as a member of the MIRECC VA Team in studies examining new treatments for substance use disorders. He was Medical Director of the Newington Mental Health Care Firm, Connecticut VA Healthcare System from Dec. 2004 through Aug. 2017. He is consulting psychiatrist to Gaylord Hospital, Wallingford, a position he previously held from 1999 - 2009. His particular expertise is in treatment of the dually-diagnosed and non-opiate pharmacological management of chronic pain. He is Associate Clinical Professor of Psychiatry, Yale University School of Medicine. He was subspecialty certified in Psychosomatic Medicine by the American Board of Psychiatry and Neurology from 2009 - 2019, in Addiction Medicine by the American Board of Addiction Medicine from 2010 - 2020, and currently in Addiction Medicine by the American Board of Preventative Medicine. Dr. Sevarino is President of the American Academy of Addiction Psychiatry (AAAP). He was Course Director for the AAAP Board Review Course in Addictions, which developed into the Addictions and Their Treatment Course, from 2007 - 2015. He currently co-directs AAAP’s Advanced Addiction Psychopharmacology course.